BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: HLXB) is a special purpose acquisition company focused on the oncology and broader life sciences sector. The blank check company filed a Form 10-Q with the Securities and Exchange Commission on November 14, 2024, providing its latest quarterly financial disclosure as it pursues a qualifying business combination in the therapeutics space. HLXB operates within the healthcare and biopharmaceutical industry, reflecting continued SPAC market interest in oncology-focused targets. For full filing history, sponsor details, current deal status, and real-time updates on HLXB and hundreds of other active vehicles, sign up for a SpacDesk account at spacdesk.com.